Ultragenyx director granted RSUs and stock options

Ultragenyx Pharmaceutical Inc. director Deborah Dunsire received new equity awards as part of her compensation.

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. director Deborah Dunsire received new equity awards as part of her compensation. She was granted 7,751 shares of Common Stock in the form of restricted stock units that vest in full on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027. She also received stock options for 14,058 shares of Common Stock at an exercise price of $25.80 per share, expiring on May 14, 2036, with the options vesting on the same schedule. Following these awards, she directly holds 38,566 shares of Common Stock and 14,058 stock options.

Insider Trade Summary

Grant/Award: 21,809 shares

Grant/Award 2 txns

Insider Dunsire Deborah

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	14,058	$0.00	$0.00
Grant/Award	Common Stock	7,751	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 14,058 contracts (Direct); Common Stock — 38,566 shares (Direct)

Footnotes (2)

1. F1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
2. F2. The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

Key Figures

RSU grant: 7,751 shares Option grant: 14,058 options Option exercise price: $25.80 per share +3 more

6 metrics

RSU grant 7,751 shares Restricted Stock Units granted on May 14, 2026

Option grant 14,058 options Stock options granted on May 14, 2026

Option exercise price $25.80 per share Exercise price for 14,058 stock options

Option expiration May 14, 2036 Expiration date of stock options

Shares held after grant 38,566 shares Total Common Stock directly held following RSU grant

Underlying option shares 14,058 shares Common Stock underlying granted stock options

Key Terms

Restricted Stock Units ("RSUs"), 2023 Incentive Plan, Stock Option (Right to Buy), Annual Meeting of Stockholders

4 terms

Restricted Stock Units ("RSUs") financial

"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2023 Incentive Plan financial

"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) transaction with 14,058.0000 shares."

Annual Meeting of Stockholders financial

"vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Deborah Dunsire receive from Ultragenyx (RARE)?

Deborah Dunsire received 7,751 restricted stock units and 14,058 stock options from Ultragenyx. The RSUs are settled in Common Stock, and the options allow her to purchase 14,058 shares at a fixed exercise price of $25.80 per share.

When do Deborah Dunsire’s new Ultragenyx (RARE) RSUs and options vest?

Both the RSUs and stock options vest in full on the earlier of Ultragenyx’s next Annual Meeting of Stockholders or May 14, 2027. This single vesting date applies to all 7,751 RSUs and all 14,058 option shares granted to her.

What is the exercise price and expiration date of Deborah Dunsire’s Ultragenyx options?

Her stock options have an exercise price of $25.80 per share and expire on May 14, 2036. She can choose to exercise these options any time after vesting and before expiration to buy Ultragenyx Common Stock at that price.

How many Ultragenyx (RARE) shares does Deborah Dunsire hold after these grants?

After the grants, Deborah Dunsire directly holds 38,566 shares of Ultragenyx Common Stock. In addition, she holds stock options covering 14,058 underlying shares, which are separate from her currently owned shares and may be exercised in the future.

Under which plan were Deborah Dunsire’s new Ultragenyx RSUs granted?

The 7,751 restricted stock units were granted under Ultragenyx’s 2023 Incentive Plan. This plan is used to provide equity-based compensation, aligning director and employee incentives with shareholder interests through stock and option awards in the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 06:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dunsire Deborah

(Last) (First) (Middle)

C/O ULTRAGENYX PHARMACEUTICAL INC.

60 LEVERONI COURT

(Street)

NOVATO CALIFORNIA 94949

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A		7,751(1)	A	$0	38,566	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$25.8	05/14/2026		A		14,058		(2)	05/14/2036	Common Stock	14,058	$0	14,058	D

Explanation of Responses:

1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

2. The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

	/s/ Karah Parschauer, attorney-in-fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)